Micrus Endovascular Announces Positive DeltaPaq Microcoil Study Results

SAN JOSE, Calif., Jul 23, 2009 (BUSINESS WIRE) -- Micrus Endovascular Corporation (NASDAQ:MEND) today announced
that study results presented recently at the 10th Congress of the World Federation of Interventional and Therapeutic
Neuroradiology (WFITN) demonstrated that the DeltaPaq(TM) microcoil's proprietary design appears to improve the uniformity
of coil distribution within a cerebral aneurysm and the degree of microcoil packing in the aneurysm dome and neck, which may
reduce the risk of aneurysm recurrence. Bernard R. Bendok, M.D., Assistant Professor of Neurological Surgery and Radiology,
Department of Neurological Surgery of Northwestern University Feinberg School of Medicine, and Matthew Gounis, Ph.D.,
Director of the New England Center for Stroke Research at the University of Massachusetts, served as principal investigators
for the Micrus-sponsored in vitro study.

"The objective of this study was to assess whether the type of coil used had an impact on packing density and coil distribution
within an aneurysm," said Dr. Bendok. "Conventional thinking has been that higher packing density reduces coil compaction
and therefore leads to fewer retreatments. This study suggests that the DeltaPaq microcoil may improve uniformity of coil
distribution and demonstrated that DeltaPaq had a statistically significant greater packing density compared with traditional
helical and complex coil designs. This is the first study to examine coil distribution in different sections of an aneurysm.
Uniformity of distribution, which was found to be superior with DeltaPaq, is a possible predictor of treatment durability."

Ron Benitez, M.D., of the Atlantic Neurosciences Institute, Overlook Hospital in Summit, NJ, commented, "In general, my
personal experience is that with Cerecyte(R) coils I see better outcomes than I did when using bare platinum coils. My approach
today is to frame with one or two Presidio Cerecyte(R) or MicruSphere(R) coils, followed almost exclusively by DeltaPaq
Cerecyte coils. The DeltaPaq coil is more conformable than other filling coils and therefore able to better find open voids in the
aneurysm, leading to a more complete packing or filling of the aneurysm. I believe that the combination of Cerecyte with
DeltaPaq's filling capabilities will undoubtedly lead to a further reduction in my recanalization and retreatment rates."

"We are singularly focused on developing and commercializing innovative products for the neurointerventional market," said
John Kilcoyne, Chairman and CEO of Micrus Endovascular. "Our DeltaPaq features a completely new coil technology we call
'Delta Wind,' which was designed to improve the interventionalist's ability to more thoroughly fill aneurysms. The market has
responded very positively to DeltaPaq, which represented 13% of our revenues in our most recently reported quarter. We are
equally excited about our DeltaPlush(TM) extra-soft, stretch-resistant finishing coil, also based on our Delta Wind technology,
which we plan to launch later this fiscal year."

About Micrus Endovascular Corporation

Micrus develops, manufactures and markets implantable and disposable medical devices for use in the treatment of cerebral
vascular diseases. Micrus products are used by interventional neuroradiologists, interventional neurologists and
neurosurgeons to treat both cerebral aneurysms responsible for hemorrhagic stroke and intracranial atherosclerosis, which
may lead to ischemic stroke. Hemorrhagic and ischemic stroke are both significant causes of death and disability worldwide.
The Micrus product lines enable physicians to gain access to the brain in a minimally invasive manner through the vessels of
the arterial system. Micrus' proprietary, three-dimensional microcoils automatically deploy within the aneurysm, forming a
scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells stents, balloon catheters, access
devices such as guide catheters, microcatheters, guidewires and accessory products used in conjunction with its microcoils.
For more information, visit www.micruscorp.com.

Forward-Looking Statements

Micrus, from time to time, may discuss forward-looking information, including estimated fiscal 2010 revenues. Except for the
historical information contained in this release, all forward-looking statements are predictions by the Company's management
and are subject to various risks and uncertainties that may cause results to differ from management's current expectations.
Such factors include the risk of inconclusive or unfavorable clinical trial results, the Company's ability to obtain, and the timing
of, regulatory approvals and clearances for its products, product enhancements or future products, and other risks affecting
the Company, including the Company's limited operating history and history of significant operating losses, fluctuations in
quarterly operating results, which are difficult to predict, currency exchange rate fluctuations, the Company's dependence on
developing new products or product enhancements, challenges associated with complying with applicable state, federal and
international regulations related to sales of medical devices and governing Micrus' relationships with physicians and other
consultants, the Company's ability to compete with large, well-established medical device manufacturers with significant
resources and other risks as detailed from time to time in risk factors and other disclosures in the Company's Annual Report on
Form 10-K for the fiscal year ended March 31, 2009, and other filings with the Securities and Exchange Commission. All
forward-looking statements in this release represent the Company's judgment as of the date of this release. The Company
disclaims, however, any intention or obligation to update forward-looking statements.

SOURCE: Micrus Endovascular Corporation

Company Contact:
Micrus Endovascular Corporation
Gordon Sangster, Chief Financial Officer
408-433-1400
or
Investor Contact:
Lippert/Heilshorn & Associates, Inc.
Jody Cain (jcain@lhai.com)
Bruce Voss (bvoss@lhai.com)
310-691-7100

Copyright Business Wire 2009